EUCTR2012-001676-11-IT进行中（未招募）不适用
MIRO study (Molecularly Oriented Immuno-radio-therapy): a multicenter phase II trail for the treatment on molecular basis of stage I / II Follicular Lymphoma with local radiotherapy with / without Ofatumumab - FIL_MIRO
FONDAZIONE ITALIANA LINFOMI ONLUS0 个研究点目标入组 110 人开始时间: 2014年9月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically confirmed follicular lymphoma grade I-IIIa;
- •Stage IA or IIA (no more than 2 contiguous nodal regions) non bulky (<7 cm);
- •FLIPI <2, FLIPI2 <2;
- •Previously untreated;
- •Age = 18;
- •Informed consent;
- •Staging with PET-CT, bone marrow biopsy;
- •Qualitative/quantitative PCR basal evaluation of Bcl-2/IgH rearranged cells in peripheral blood and bone marrow.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Follicular lymphoma grade IIIb;
- •Stage greater than II with more than 2 nodal sites and/or B symptoms and/or bulky disease (>7 cm);
- •FLIPI >2, FLIPI2 >2;
- •Age < 18;
- •Previous treatments for non-Hodgkin’s lymphoma;
- •Impossibility to subscribe the informed consent;
- •Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones or stable chronic liver disease per investigator assessment)
- •Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical study
- •Other past or current malignancy. Subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible.
- •Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C.
- •History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
- •Known HIV positive
- •Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to start of treatment, congestive heart failure (NYHA III-IV), and arrhythmia unless controlled by therapy, with the exception of extra systoles or minor conduction abnormalities.
- •Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease which in the opinion of the investigator may represent a risk for the patient.
- •Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a quantitative HBV-DNA test will be performed and if positive the subject will be excluded. Patients with HBcAb positivity and negative HBV DNA should be prophilactically treated with oral Lamivudine (100 mg /day) in case of treatment with Ofatumumab, to be prosecuted 12 months after treatment.
- •Positive serology for hepatitis C (HC) defined as a positive test for HCAb, in which case reflexively perform a HCV-RNA on the same sample to confirm the result;
- •Hematologic and blood chemistry esclusion criteria:
- •platelets <50 x 109/L;
- •neutrophils <1.0 x 109/L;
- •creatinine >2.0 times upper normal limit;
- •total bilirubin >1.5 times upper normal limit;
- •ALT >2.5 times upper normal limit;
- •alkaline phosphatase >2.5 times upper normal limit.
- •Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test at screening.
- •Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from study start to one year after the last dose of protocol therapy. Adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence
- •Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy.
研究者
相似试验
已完成
2 期
"MIRO" Molecularly Oriented Immuno-radio-therapyFollicular Lymphoma, Grade 1Follicular Lymphoma, Grade 2Follicular Lymphoma Grade 3ANCT02710643Fondazione Italiana Linfomi - ETS110
进行中（未招募）
1 期
Effect of rituximab in secondary progressive multiple sclerosisMultiple SclerosisEUCTR2012-004436-36-DKOdense University Hospital15
尚未招募
不适用
The investigation of immunoligical and molecular mecahanisms between obsessive-compulsive disorder and its comorbidity.obsessive-compulsive disorderJPRN-UMIN000046381HYOGO MEDICAL UNIVERSITY200
招募中
不适用
Molecular immunological characterisation and multi-centric patient-centered care of children and adolescents with Long COVID in Baden-WürttembergG93.3Postviral fatigue syndromeDRKS00033269niversitätsklinikum Freiburg, Zentrum für Kinder- und Jugendmedizin200
进行中（未招募）
不适用
(Maraviroc ENHancement of Immunological Response): A pilot study of maraviroc as an add-on in patients with reduced CD4 cell count despite full viral suppression - MENHIREUCTR2010-019518-25-ITAZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO (A.O. DI RILIEVO NAZIONALE)